MYCN and neuroblastoma: More than half of high-risk patients (International Neuroblastoma Staging System (INSS) stage 4 and INRG stage M patients ≥18 months of age and all NB-patients with a MYCN amplification) die from disease despite intensive multimodal treatment, including chemotherapy, surgery and myeloablative chemotherapy with autologous stem cell rescue, as well as 131-metaiodobenzylguanidine therapy or external beam radiation.